Dr. Shore on next steps with PARP inhibitors in prostate cancer

SAP Partner | <b>GenesisCare</b>

Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).